Press Releases

Date Title and Summary
Toggle Summary Accuray Enhances Capital Structure Through Convertible Debt Transactions
­Transactions Facilitate Reduction of Short-term Debt and Potential Dilution to Shareholders SUNNYVALE, Calif. , July 28, 2017 /PRNewswire/ -- Accuray Incorporated  (NASDAQ: ARAY) has entered into privately negotiated agreements with a limited number of existing holders of the company's outstanding
Toggle Summary New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function SUNNYVALE, Calif.
Toggle Summary Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results
Q4 Revenue Expected to be Approximately $111.5-$112 Million and Q4 Gross Orders Expected to be Approximately $86 Million; Accuray Expects to Finish Fiscal Year with Approximately $108 Million in Cash, Cash Equivalents & Investments Preliminary Revenue and Product Order Results for Fourth
Toggle Summary Neuro Spinal Hospital in Dubai to Acquire Accuray CyberKnife® and Radixact™ Systems
Leading Hospital will be the First in the Middle East to Offer Patients Precise Treatments with the Latest Generations of Both Systems SUNNYVALE, Calif. , July 11, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding access to its products in the Middle
Toggle Summary Montefiore is First in NY Metropolitan Area to Treat Cancer Patients with Accuray Radixact™ System
Cutting-Edge Radiation Therapy System Dramatically Improves Precision, Efficiency and Safety, While Minimizing Side Effects SUNNYVALE, Calif. and NEW YORK , June 27, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) and Montefiore Einstein Center for Cancer Care (MECCC), part of the
Toggle Summary IUCT Oncopole Advances Cancer Care in France with the New Accuray Radixact™ System
The French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray SUNNYVALE, Calif. , June 20, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the University Cancer Institute of Toulouse
Toggle Summary Anova Marks 1,500th Prostate Cancer Patient Treated with the Accuray CyberKnife® System
- Accuray and Anova Cancer Care Remember Prostate Patients this Father's Day - CyberKnife System Provides Grandfathers, Fathers, Brothers, Uncles and Sons with Precise Radiation Treatments in Fewer Treatment Sessions than Conventional Radiation Therapy SUNNYVALE, Calif.
Toggle Summary Accuray Enters into New Revolving Loan Agreement
New Loan Expected to Reduce Interest Costs by Approximately $2.0 Million Annually SUNNYVALE, Calif. , June 15, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today it has closed a new $52 million senior secured revolving loan facility with MidCap Financial Trust .
Toggle Summary Accuray Appoints Stan Gee VP of Revenue Management
SUNNYVALE, Calif. , May 24, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed, Stan Gee , who has been with Accuray for over eight years, to the newly created Vice President of Revenue Management position reporting to Kevin Waters , Chief Financial Officer.
Toggle Summary New Data Reinforce Benefits of TomoTherapy® Platform for Mainstream Radiation Therapy Treatment Indications
Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control withReduced Toxicities SUNNYVALE, Calif. , May 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies continue to demonstrate the unmatched flexibility of the cutting-edge

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.